Triceutical Recalls Lecithin Reishi Complex Soft Gels for Manufacturing Issues
Triceutical Inc. is recalling all lots of Lecithin Reishi Complex soft gels due to a lack of good manufacturing practices.
The agency’s classification
FDA (Food): Class III
Class III is a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 2/5 (Moderate).
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class III, which indicates the product is unlikely to cause adverse health consequences. The reason for the recall is a lack of good manufacturing practices, which fits the criteria for a moderate severity voluntary precautionary recall.
Plain-English summary
Triceutical Inc. is voluntarily recalling all lots of Lecithin Reishi Complex soft gels. The recall was initiated because the product was manufactured without adhering to good manufacturing practices. The affected product consists of 1,390 bottles.
The recalled product was distributed domestically in Florida, New York, and Pennsylvania, as well as internationally in China. All lot numbers and expiration dates are included in this recall.
Consumers who have purchased this product should stop using it and contact the manufacturer for further instructions or a refund.
The recalled product
- Product
- Lecithin Reishi Complex soft gels
- Manufacturer
- Triceutical Inc./Zhang
- Category
- Food — Dietary Supplement
- Hazard
- Affected units
- 1,390
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- all lot numbers
- all expiration dates
Distribution
Part of a larger recall action
This product is one of 21 recalled by Triceutical Inc./Zhang under a single FDA (Food) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 21 products in this recall →Related recalls
Same manufacturer · Triceutical Inc./Zhang
See all →- LowTriceutical Recalls Hyaluronic Acid Supplements Due to Manufacturing Deficiencies
FDA (Food) · 2016-10-26
- LowTriceutical Recalls Premium Protein III Supplement for Manufacturing Deficiencies
FDA (Food) · 2016-10-26
- ModerateTriceutical Recalls Rishi Mushroom Spore Supplements for Manufacturing Violations
FDA (Food) · 2016-10-26
- LowTriceutical Inc. Recalls CardioAdvance Dietary Supplements for Manufacturing Violations
FDA (Food) · 2016-10-26
- ModerateTriceutical Inc. Recalls Eagle Lecithin Soft Gels for Manufacturing Violations
FDA (Food) · 2016-10-26
Same hazard · manufacturing defect
See all →- HighBeak & Skiff Alcohol Antiseptic Sanitizer recalled for acetaldehyde contamination
FDA (Drugs) · 2026-10-14
- HighFDA Recalls Opportunity Pro Nitrile Gloves Due to Manufacturing Defects
FDA (Devices) · 2026-10-07
- HighWright Medical Recalls Charlotte Claw Screws Due to Missing Threads
FDA (Devices) · 2026-10-07
- ModerateCustom Interventional Pain Management Recalls Mastisol Skin Adhesive Trays
FDA (Devices) · 2026-10-07
- HighNOxBOXi Nitric Oxide Delivery System Recalled for Oxygen Sensor Defect
FDA (Devices) · 2026-10-07
Similar recalls
- ModerateHealthmaxx Recalls Hyper II Lecithin Softgels Due to Mislabeling
FDA (Food) · 2013-10-02
- ModerateHealth One Pharmaceuticals Recalls Lecithin Supplements for cGMP Violations
FDA (Food) · 2015-04-08
- HighSynergy Rx Recalls Tretinoin Cream and Gel Due to Sterility Concerns
FDA (Drugs) · 2017-03-22
- ModerateGood Herbs REISHI Recalled for Failure to Meet GMP Standards
FDA (Food) · 2014-11-05
- ModerateUS Pharmaceuticals Recalls Cool Hot Ice Analgesic Gel Due to Water Quality Issues
FDA (Drugs) · 2019-08-21
- ModerateFDA Recalls Humatrix Microclysmic Gel for Manufacturing Practice Violations
FDA (Drugs) · 2023-02-22